SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes

Saved in:
Bibliographic Details
Published inDeutsche medizinische Wochenschrift (1946) Vol. 139 Suppl 2; p. S52
Main Author Seufert, J
Format Journal Article
LanguageGerman
Published Germany 01.02.2014
Subjects
Blood Glucose - metabolism
Blood Pressure - drug effects
Body Weight - drug effects
Canagliflozin
Clinical Trials, Phase III as Topic
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Nephropathies - blood
Diabetic Nephropathies - drug therapy
Dose-Response Relationship, Drug
Double-Blind Method
Glucosides - adverse effects
Glucosides - therapeutic use
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Kidney - drug effects
Kidney Concentrating Ability - drug effects
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 - antagonists & inhibitors
Thiophenes - adverse effects
Thiophenes - therapeutic use
Online AccessGet more information

Cover

More Information
ISSN:1439-4413
DOI:10.1055/s-0033-1359991